Compare Stocks: AVXL, CGEM, OLMA, and JBIO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVXL Anavex Life Sciences	$2.95 +7.3%	$2.61	$2.26 ▼ $11.70	$254.85M	1.15	955,098 shs	1.44 million shs
CGEM Cullinan Therapeutics	$16.25 -1.5%	$16.43	$5.68 ▼ $19.43	$1.01B	0.01	576,307 shs	386,685 shs
JBIO Jade Biosciences	$19.15 -3.0%	$19.64	$6.67 ▼ $28.00	$974.86M	1.43	892,083 shs	651,160 shs
OLMA Olema Pharmaceuticals	$11.28 -1.5%	$11.37	$4.47 ▼ $36.26	$1.00B	2.03	1.02 million shs	762,684 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVXL Anavex Life Sciences	+7.27%	+18.00%	+6.88%	-12.20%	-73.66%
CGEM Cullinan Therapeutics	-1.52%	-6.77%	-7.83%	+8.77%	+111.86%
JBIO Jade Biosciences	-3.04%	-4.01%	-10.97%	-24.19%	+177.94%
OLMA Olema Pharmaceuticals	-1.48%	-6.08%	-10.76%	-22.95%	+111.63%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVXL Anavex Life Sciences	$2.95 +7.3%	$2.61	$2.26 ▼ $11.70	$254.85M	1.15	955,098 shs	1.44 million shs
CGEM Cullinan Therapeutics	$16.25 -1.5%	$16.43	$5.68 ▼ $19.43	$1.01B	0.01	576,307 shs	386,685 shs
JBIO Jade Biosciences	$19.15 -3.0%	$19.64	$6.67 ▼ $28.00	$974.86M	1.43	892,083 shs	651,160 shs
OLMA Olema Pharmaceuticals	$11.28 -1.5%	$11.37	$4.47 ▼ $36.26	$1.00B	2.03	1.02 million shs	762,684 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVXL Anavex Life Sciences	+7.27%	+18.00%	+6.88%	-12.20%	-73.66%
CGEM Cullinan Therapeutics	-1.52%	-6.77%	-7.83%	+8.77%	+111.86%
JBIO Jade Biosciences	-3.04%	-4.01%	-10.97%	-24.19%	+177.94%
OLMA Olema Pharmaceuticals	-1.48%	-6.08%	-10.76%	-22.95%	+111.63%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVXL Anavex Life Sciences	2.40	Hold	$21.33	623.16% Upside
CGEM Cullinan Therapeutics	2.63	Moderate Buy	$32.14	97.80% Upside
JBIO Jade Biosciences	2.90	Moderate Buy	$51.57	169.30% Upside
OLMA Olema Pharmaceuticals	2.71	Moderate Buy	$44.10	290.96% Upside

Current Analyst Ratings Breakdown

Latest AVXL, CGEM, OLMA, and JBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/29/2026	CGEM Cullinan Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$38.00 ➝ $39.00
7/17/2026	OLMA Olema Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/8/2026	CGEM Cullinan Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/16/2026	JBIO Jade Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (D-)
6/15/2026	JBIO Jade Biosciences	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$45.00
6/15/2026	JBIO Jade Biosciences	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$45.00
6/11/2026	AVXL Anavex Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/11/2026	CGEM Cullinan Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$37.00
6/8/2026	CGEM Cullinan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$30.00
6/2/2026	JBIO Jade Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$55.00
6/2/2026	JBIO Jade Biosciences	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$47.00

(Data available from 8/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	$1.10 per share	N/A
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	$6.92 per share	N/A
JBIO Jade Biosciences	N/A	N/A	N/A	N/A	$6.74 per share	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	$5.88 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVXL Anavex Life Sciences	-$46.38M	-$0.39	N/A	N/A	N/A	N/A	-32.73%	-30.15%	8/10/2026 (Estimated)
CGEM Cullinan Therapeutics	-$219.88M	-$3.36	N/A	N/A	N/A	N/A	-51.45%	-47.64%	8/6/2026 (Estimated)
JBIO Jade Biosciences	-$127.41M	-$2.02	N/A	N/A	N/A	N/A	-51.34%	-47.32%	N/A
OLMA Olema Pharmaceuticals	-$162.45M	-$2.02	N/A	N/A	N/A	N/A	-46.00%	-41.22%	8/10/2026 (Estimated)

Latest AVXL, CGEM, OLMA, and JBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	AVXL Anavex Life Sciences	-$0.08	N/A	N/A	N/A	N/A	N/A
8/10/2026	Q2 2026	OLMA Olema Pharmaceuticals	-$0.53	N/A	N/A	N/A	N/A	N/A
8/6/2026	Q2 2026	CGEM Cullinan Therapeutics	-$0.7993	N/A	N/A	N/A	$3.67 million	N/A
7/30/2026	Q2 2026	AVXL Anavex Life Sciences	-$0.07	-$0.06	+$0.01	-$0.06	N/A	N/A
5/12/2026	Q1 2026	OLMA Olema Pharmaceuticals	-$0.52	-$0.52	N/A	-$0.52	N/A	N/A
5/7/2026	Q1 2026	CGEM Cullinan Therapeutics	-$0.8359	-$0.75	+$0.0859	-$0.75	$3.67 million	N/A
5/7/2026	Q1 2026	JBIO Jade Biosciences	-$0.52	-$0.57	-$0.05	-$0.57	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	N/A
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	N/A
JBIO Jade Biosciences	N/A	N/A	N/A	N/A	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVXL Anavex Life Sciences	N/A	20.87	20.87
CGEM Cullinan Therapeutics	N/A	10.28	10.28
JBIO Jade Biosciences	N/A	14.29	14.29
OLMA Olema Pharmaceuticals	0.01	10.88	10.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVXL Anavex Life Sciences	31.55%
CGEM Cullinan Therapeutics	86.31%
JBIO Jade Biosciences	N/A
OLMA Olema Pharmaceuticals	91.78%

Insider Ownership

Company	Insider Ownership
AVXL Anavex Life Sciences	11.00%
CGEM Cullinan Therapeutics	8.60%
JBIO Jade Biosciences	23.06%
OLMA Olema Pharmaceuticals	12.56%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVXL Anavex Life Sciences	40	92.67 million	82.48 million	Optionable
CGEM Cullinan Therapeutics	30	61.46 million	56.17 million	Optionable
JBIO Jade Biosciences	20	49.36 million	37.98 million	N/A
OLMA Olema Pharmaceuticals	70	87.35 million	76.38 million	Optionable

AVXL, CGEM, OLMA, and JBIO Headlines

Recent News About These Companies

Olema Pharmaceuticals (OLMA) Expected to Release Quarterly Earnings on Monday

August 3 at 9:55 AM | marketbeat.com

Defilade Capital Management L.P. Acquires 269,902 Shares of Olema Pharmaceuticals, Inc. $OLMA

August 3 at 4:23 AM | marketbeat.com

Janus Henderson Group PLC Boosts Holdings in Olema Pharmaceuticals, Inc. $OLMA

August 1 at 6:08 AM | marketbeat.com

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Consensus Recommendation of "Moderate Buy" by Brokerages

July 31, 2026 | marketbeat.com

Insider Selling: Olema Pharmaceuticals (NASDAQ:OLMA) Director Sells 12,500 Shares of Stock

July 28, 2026 | marketbeat.com

Wall Street Zen Downgrades Olema Pharmaceuticals (NASDAQ:OLMA) to Strong Sell

July 25, 2026 | americanbankingnews.com

Olema Pharmaceuticals (NASDAQ:OLMA) Downgraded by Wall Street Zen to "Strong Sell"

July 25, 2026 | marketbeat.com

Siren L.L.C. Boosts Stake in Olema Pharmaceuticals, Inc. $OLMA

July 24, 2026 | marketbeat.com

339,461 Shares in Olema Pharmaceuticals, Inc. $OLMA Bought by SEB Asset Management AB

July 23, 2026 | marketbeat.com

Jennison Associates LLC Has $27.17 Million Stock Holdings in Olema Pharmaceuticals, Inc. $OLMA

July 21, 2026 | marketbeat.com

Olema Pharmaceuticals (NASDAQ:OLMA) Shares Up 5.9% - Here's Why

July 17, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Oncolytics Biotech (ONCY) and Olema Pharmaceuticals (OLMA)

July 14, 2026 | theglobeandmail.com

Wall Street Zen Upgrades Olema Pharmaceuticals (NASDAQ:OLMA) to "Sell"

July 12, 2026 | marketbeat.com

Does Olema Pharmaceuticals' (OLMA) Broad Russell Growth Inclusion Reveal a Turning Point in Its Investor Story?

June 30, 2026 | finance.yahoo.com

How Olema Pharmaceuticals (OLMA) Is Adding Pipeline Depth Behind Its Palazestrant Breast Cancer Bet

June 17, 2026 | insidermonkey.com

Olema Pharmaceuticals, Inc. (OLMA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

June 9, 2026 | seekingalpha.com

LifeSci Capital Sticks to Its Buy Rating for Olema Pharmaceuticals (OLMA)

June 8, 2026 | theglobeandmail.com

Analysts Offer Insights on Healthcare Companies: Olema Pharmaceuticals (OLMA), Jade Biosciences (JBIO) and Oculis Holding (OCS)

June 8, 2026 | theglobeandmail.com

Analysts Offer Insights on Healthcare Companies: Olema Pharmaceuticals (OLMA) and Agios Pharma (AGIO)

June 4, 2026 | theglobeandmail.com

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 2, 2026 | globenewswire.com

Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration ...

May 26, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVXL, CGEM, OLMA, and JBIO Company Descriptions

Anavex Life Sciences NASDAQ:AVXL

$2.95 +0.20 (+7.27%)

Closing price 08/3/2026 04:00 PM Eastern

Extended Trading

$2.87 -0.08 (-2.85%)

As of 08:16 AM Eastern

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Cullinan Therapeutics NASDAQ:CGEM

$16.25 -0.25 (-1.52%)

Closing price 08/3/2026 04:00 PM Eastern

Extended Trading

$16.23 -0.02 (-0.13%)

As of 08:04 AM Eastern

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Jade Biosciences NASDAQ:JBIO

$19.15 -0.60 (-3.04%)

Closing price 08/3/2026 04:00 PM Eastern

Extended Trading

$20.56 +1.42 (+7.39%)

As of 07:23 AM Eastern

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Olema Pharmaceuticals NASDAQ:OLMA

$11.28 -0.17 (-1.48%)

Closing price 08/3/2026 04:00 PM Eastern

Extended Trading

$11.30 +0.02 (+0.18%)

As of 04:15 AM Eastern

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AVXL, CGEM, OLMA, and JBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AVXL, CGEM, OLMA, and JBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AVXL, CGEM, OLMA, and JBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVXL, CGEM, OLMA, and JBIO Company Descriptions

Anavex Life Sciences NASDAQ:AVXL

Cullinan Therapeutics NASDAQ:CGEM

Jade Biosciences NASDAQ:JBIO

Olema Pharmaceuticals NASDAQ:OLMA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AVXL, CGEM, OLMA, and JBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AVXL, CGEM, OLMA, and JBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AVXL, CGEM, OLMA, and JBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVXL, CGEM, OLMA, and JBIO Company Descriptions

Anavex Life Sciences NASDAQ:AVXL

Cullinan Therapeutics NASDAQ:CGEM

Jade Biosciences NASDAQ:JBIO

Olema Pharmaceuticals NASDAQ:OLMA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools